The WACC of MetaStat Inc (MTST) is 4.6%.
Range | Selected | |
Cost of equity | 422.6% - 1185.8% | 804.2% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 4.2% - 5.0% | 4.6% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 91.02 | 210.89 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 422.6% | 1185.8% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 850.77 | 850.77 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 4.2% | 5.0% |
Selected WACC | 4.6% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
MTST | MetaStat Inc | 850.77 | -77.19 | -0.12 |
ARCH.V | Arch Biopartners Inc | 0.02 | 0.68 | 0.67 |
CDXC | Chromadex Corp | 0 | 0.57 | 0.57 |
CRL | Charles River Laboratories International Inc | 0.29 | 0.43 | 0.36 |
ESSI | Eco Science Solutions Inc | 324.48 | 1.04 | 0 |
EVIO | EVIO Inc | 595.18 | 0 | 0 |
ICLR | ICON PLC | 0.29 | 0.67 | 0.56 |
IQV | IQVIA Holdings Inc | 0.5 | 0.65 | 0.47 |
PSNL | Personalis Inc | 0 | 0.98 | 0.98 |
Low | High | |
Unlevered beta | 0.38 | 0.54 |
Relevered beta | 135.36 | 314.27 |
Adjusted relevered beta | 91.02 | 210.89 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for MTST:
cost_of_equity (804.20%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (91.02) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.